Foslinanib

DB16172InvestigationalSmall molecule

Foslinanib is under investigation in clinical trial NCT03600233 (Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors).

Mechanism: Pharmacologically active on Heat shock protein 75 kDa, mitochondrial
Curator reviewed
Formula / weight: C₁₆H₁₃FNO₆P · 365.253 g/mol (avg)
Also known as: Trx-818 free acid
Code names: CVM-1118 · CVM-1118 FREE ACID · TRX-818

Resolves to

Compound

Structure

InChIKeyZDWFMAHQGDEALT-UHFFFAOYSA-NSMILESCOC1=C(OP(O)(O)=O)C2=C(NC(=CC2=O)C2=CC(F)=CC=C2)C=C1

Targets

What you can answer from here — as of July 24, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Foslinanib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.